Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) CEO Christopher J. Moreau presents to investors at Proactive One2One Virtual Event. The drug re-purposing company investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
Proactive One2One Virtual Event - Algernon Pharmaceuticals
Quick facts: Algernon Pharmaceuticals Inc.
Price: 0.235 CAD
Market Cap: $32.51 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...FOR OUR FULL DISCLAIMER CLICK HERE